Brandon Shank, PharmD, MPH, BCOP, Clinical Pharmacy Specialist, discusses the need for pharmacy schools to adapt their curriculum to address biosimilar treatments.
Transcript
Do pharmacy schools need to change their curriculum to address biosimilars?
The pharmacy school curriculum should adapt to the growing increase in biosimilars by adding coursework to compare and contrast small molecules versus large, complex proteins, as well as approval process and requirements for bringing biosimilars to market. On rotation, pharmacy students should encounter biosimilars and have some experience with dispensing those agents.
Where clinical, regulatory, and economic perspectives converge—sign up for Center for Biosimilars® emails to get expert insights on emerging treatment paradigms, biosimilar policy, and real-world outcomes that shape patient care.
Adalimumab Biosimilar Maintains Effectiveness for Patients With Arthritis and Health Care Costs
August 1st 2025Patients with rheumatoid and psoriatic arthritis maintained stable disease activity and functional capacity, with even some improvement in ultrasound findings, after switching from original adalimumab to its biosimilar, GP2017.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
August 1st 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?